Vulvar Carcinoma

NCI Definition: A carcinoma arising from the vulva. It usually affects elderly women but has been observed in premenopausal women as well. The most frequently seen histologic type is squamous cell carcinoma. The most common site of involvement is the labia majora. In many cases, the development of vulvar cancer is preceded by condyloma or squamous dysplasia. [1]

Clinical Trials

View Clinical Trials for Vulvar Carcinoma

There are 18 clinical trials for vulvar carcinoma, of which 14 are open and 4 are completed or closed. Of the trials that contain vulvar carcinoma as an inclusion criterion, 9 are phase 1 (8 open), 6 are phase 1/phase 2 (3 open), 2 are phase 2 (2 open), and 1 is no phase specified (1 open).

HPV, CDKN2A, and ARID1A are the most frequent gene inclusion criteria for vulvar carcinoma clinical trials [3].

Trials Investigating Vulvar Carcinoma by Gene and Recruiting Status

Durvalumab, bintrafusp alfa, and cisplatin are the most common interventions in vulvar carcinoma clinical trials.

Drugs Being Investigated in Vulvar Carcinoma Trials by Recruiting Status

Significant Genes in Vulvar Carcinoma

ARID1A +

ARID1A is an inclusion eligibility criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ARID1A status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

ATM +

ATM is an inclusion eligibility criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ATM status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

ATR +

ATR is an inclusion eligibility criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ATR status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

ATRX +

ATRX is an inclusion eligibility criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ATRX status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

BARD1 +

BARD1 is an inclusion eligibility criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains BARD1 status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

BRCA1 +

BRCA1 is an inclusion eligibility criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains BRCA1 status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

BRCA2 +

BRCA2 is an inclusion eligibility criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains BRCA2 status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

BRIP1 +

BRIP1 is an inclusion eligibility criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains BRIP1 status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

C11ORF30 +

C11orf30 is an inclusion eligibility criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains C11orf30 status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

CCNE1 +

CCNE1 is an inclusion eligibility criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CCNE1 status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

CDK12 +

CDK12 is an inclusion eligibility criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CDK12 status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

CHEK1 +

CHEK1 is an inclusion eligibility criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CHEK1 status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

CHEK2 +

CHEK2 is an inclusion eligibility criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CHEK2 status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

ERCC2 +

ERCC2 is an inclusion eligibility criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ERCC2 status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

ERCC3 +

ERCC3 is an inclusion eligibility criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ERCC3 status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

ERCC4 +

ERCC4 is an inclusion eligibility criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ERCC4 status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

ERCC5 +

ERCC5 is an inclusion eligibility criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ERCC5 status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

ERCC6 +

ERCC6 is an inclusion eligibility criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ERCC6 status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

FANCA +

FANCA is an inclusion eligibility criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FANCA status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

FANCB +

FANCB is an inclusion eligibility criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FANCB status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

FANCC +

FANCC is an inclusion eligibility criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FANCC status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

FANCD2 +

FANCD2 is an inclusion eligibility criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FANCD2 status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

FANCE +

FANCE is an inclusion eligibility criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FANCE status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

FANCF +

FANCF is an inclusion eligibility criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FANCF status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

FANCG +

FANCG is an inclusion eligibility criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FANCG status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

FANCI +

FANCI is an inclusion eligibility criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FANCI status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

FANCL +

FANCL is an inclusion eligibility criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FANCL status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

FANCM +

FANCM is an inclusion eligibility criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FANCM status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

HDAC1 +

HDAC1 is an inclusion eligibility criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains HDAC1 status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

HDAC2 +

HDAC2 is an inclusion eligibility criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains HDAC2 status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

MDM2 +

MDM2 is an inclusion eligibility criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MDM2 status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

MDM4 +

MDM4 is an inclusion eligibility criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MDM4 status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

MLF1 +

MLF1 is an inclusion eligibility criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MLF1 status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

MLH1 +

MLH1 is an inclusion eligibility criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MLH1 status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

MLH3 +

MLH3 is an inclusion eligibility criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MLH3 status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

MRE11A +

MRE11A is an inclusion eligibility criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MRE11A status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

MSH2 +

MSH2 is an inclusion eligibility criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MSH2 status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

MSH3 +

MSH3 is an inclusion eligibility criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MSH3 status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

MSH6 +

MSH6 is an inclusion eligibility criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MSH6 status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

MUTYH +

MUTYH is an inclusion eligibility criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MUTYH status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

MYC +

MYC is an inclusion eligibility criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MYC status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

NBN +

NBN is an inclusion eligibility criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NBN status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

NPM1 +

NPM1 is an inclusion eligibility criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NPM1 status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

PALB2 +

PALB2 is an inclusion eligibility criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PALB2 status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

PARP1 +

PARP1 is an inclusion eligibility criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PARP1 status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

PARP2 +

PARP2 is an inclusion eligibility criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PARP2 status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

PMS1 +

PMS1 is an inclusion eligibility criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PMS1 status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

PMS2 +

PMS2 is an inclusion eligibility criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PMS2 status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

POLE +

POLE is an inclusion eligibility criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains POLE status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

PPP2R1A +

PPP2R1A is an inclusion eligibility criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PPP2R1A status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

PPP2R2A +

PPP2R2A is an inclusion eligibility criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PPP2R2A status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

RAD50 +

RAD50 is an inclusion eligibility criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RAD50 status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

RAD51 +

RAD51 is an inclusion eligibility criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RAD51 status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

RAD51B +

RAD51B is an inclusion eligibility criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RAD51B status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

RAD51C +

RAD51C is an inclusion eligibility criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RAD51C status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

RAD51D +

RAD51D is an inclusion eligibility criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RAD51D status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

RAD54L +

RAD54L is an inclusion eligibility criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RAD54L status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

RB1 +

RB1 is an inclusion eligibility criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RB1 status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

SLX4 +

SLX4 is an inclusion eligibility criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SLX4 status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

SMARCB1 +

SMARCB1 is an inclusion eligibility criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SMARCB1 status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

STAG2 +

STAG2 is an inclusion eligibility criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains STAG2 status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

STK11 +

STK11 is an inclusion eligibility criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains STK11 status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

TP53 +

TP53 is an inclusion eligibility criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains TP53 status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

XRCC1 +

XRCC1 is an inclusion eligibility criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains XRCC1 status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

Disease Details

Synonyms

Cancer of the Vulva, Vulvar Cancer, Carcinoma of the Vulva, Vulva Cancer, Vulvar cancer, NOS, Cancer of Vulva, Vulva Carcinoma, Carcinoma of Vulva

Parent(s)

Vulvar/Vaginal Carcinoma

Children

Vulvar Basal Cell Carcinoma, Vulvar Squamous Cell Carcinoma, Vulvar Adenocarcinoma, Bartholin Gland Carcinoma, Labia Majora Carcinoma, and Labia Minora Carcinoma

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.

Diseases /

Vulvar Carcinoma

Back to Diseases List

Associated Genetic Biomarkers

Overview

Clinical Trials

Significant Genes in Vulvar Carcinoma

Disease Details

References

About

Molecular Medicine

Content Types